Boulding Mark Elliott: insider trades.
Boulding Mark Elliott reported 13 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($636K), across 1 company.
- Transactions
- 13
- Purchases (P)
- 0
- Sales (S)
- 10
- Companies
- 1
- Name as filed
- Boulding Mark Elliott
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Ptc Therapeutics, Inc. (PTCT) | Officer · EXEC. VP AND CLO | 13 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-17 | Ptc Therapeutics, Inc. | M | 2,813 | $25.69 | 108,085 | Form 4 |
| 2026-08-17 | Ptc Therapeutics, Inc. | S | 969 | $72.9 | 105,272 | Form 4 |
| 2026-08-17 | Ptc Therapeutics, Inc. | S | 1,844 | $72.39 | 106,241 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | S | 833 | $84.41 | 106,392 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | S | 313 | $83.1 | 107,225 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | M | 2,266 | $39.42 | 107,538 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | S | 745 | $86.38 | 105,272 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | S | 519 | $85.84 | 105,873 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | S | 1,036 | $84.41 | 106,662 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | S | 387 | $83.1 | 107,698 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | M | 2,813 | $46.54 | 108,085 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | S | 601 | $86.38 | 105,272 | Form 4 |
| 2026-07-06 | Ptc Therapeutics, Inc. | S | 645 | $85.84 | 106,017 | Form 4 |
Questions
What stock did Boulding Mark Elliott buy or sell?
Boulding Mark Elliott reported 13 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($636K), across 1 company.
Is Boulding Mark Elliott the same person as other filers with this name?
This page covers SEC CIK 1578852 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/boulding-mark-elliott-1578852.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.